The success of mRNA vaccines has triggered a wave of patent disputes as companies seek to establish ownership of the technologies underpinning this rapidly growing field. The article explores the key drivers behind this litigation and its implications for innovation, licensing, and competition in the mRNA sector.
Messenger RNA (“mRNA”) is a naturally occurring molecule that carries instructions from DNA, telling cells which proteins to make.
Scientists have explored whether this process could be harnessed for medical purposes — including using mRNA as a way of instructing the body to produce certain proteins, on demand.
In theory, this offers a powerful and flexible approach to medicine. Instead of developing a different drug for each disease, mRNA technology could provide a new platform: introducing genetic “instructions” to prompt the body to produce specific proteins, for example to train the immune system to recognise a virus or to target cancer cells.